�鶹��madou

Professor Raina MacIntyre (MBBS Hons 1, FRACP, FAFPHM, M App Epid, PhD) is��NHMRC Leadership 3 Fellow and Professor of Global Biosecurity. She heads the��Biosecurity Program��at the Kirby Institute, which conducts research in epidemiology, bioinformatics, health intelligence, vaccinology, bioterrorism prevention, mathematical modelling, genetic epidemiology, public health and clinical trials in infectious diseases. Her innovation,��, which she conceived and developed from 2016 onward��is an advanced AI system for real-time global health intelligence.��She is an innovator with a talent and vision for advanced health intelligence that can be applied in real-time to solve pressing problems.��She has won many awards including the����in 2022. As of the start of 2024, she is the #1 ranked researcher in the world on Respiratory Protective Devices and highly ranked in Smallpox and several other areas of infectious diseases (Expertscape). Her H index is 81/64 (GS/Scopus) with >30,000 citations. FWCI: 3.69 since 2011, 4.7 since 2020, 30.46 ��for topic influenza and 18.8 citations per publication in the past 5 years. She has 21.4% of her publications in the top 10% most cited papers (Scopus) in the past 5 years.��In 2020 a quote from her invited editorial on masks was featured on the cover of Lancet (Vol 195 June 27 2020), reflecting her global recognition as an expert in masks. Lancet Infectious Diseases published a��of her in 2021 (VOL 21:4, P468, APRIL 01, 2021).

Her research falls under��4 areas:����Personal protective equipment,��Vaccinology,��Epidemic response and emerging infectious diseases, and bioterrorism prevention.��She is a dual-specialist physician with training in epidemiology and modelling. Her research is underpinned by her clinical��training, vaccine program experience, extensive field outbreak investigation and health intelligence/surveillance experience.�� She is on the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC 2021-2024), WHO SAGE ad-hoc Working Group on Smallpox and Monkeypox, and is the focal point for WHO GOARN in the �鶹��madou GOARN member group.��

She has led and developed an automated, real-time rapid epidemic intelligence platform,����which uses AI to scan open-source data for early epidemic signals. There are 3 AI systems in ���ʱ��´��հ��®️ - NLP, a prioritisation algorithm and LLMs. She currently has a Microsoft Accelerating Foundation Models Research Grant to develop advanced AI for ���ʱ��´��հ��®️ using GPT4. She funds and leads a team of analysts, epidemiologists, LLM/AI specialists and software engineers to��further develop ���ʱ��´��հ��®️ into a global hub of real-time epidemic detection, prevention and mitigation, with a suite of real-time decision support and risk analysis tools. Her vision for�����ʱ��´��հ��®️ is to be a health intelligence service for global health protection and for public good.��A philanthropic gift from����Balvi Filantropic Fund in 2022-23 has allowed her to expand on ���ʱ��´��հ��®️ globally in low and middle income countries, making ���ʱ��´��հ��®️ accessible and equitable.��This is called the Shiba Inu EPIWATCH OSINT project and is focused on open-sourcing of EPIWATCH®️. In 2024 she is working with US Indopacific Command on a WarGame, Able Resolve 2024, which features ���ʱ��´��հ��®️. Innovations that she is researching now include real-time image-based analysis and application of her platform to other intelligence streams. There is vast capability in ���ʱ��´��հ��®️ to apply her unique vision and talent to much wider applications in defence, biodefense and intelligence.��

Raina has a 31-year track record in pandemics, epidemic infections, serious emerging infections, vaccines and control of respiratory viruses. She has worked as a clinician in hospitals, in health departments on outbreak control, and her PhD research was on screening, surveillance and contact tracing for TB and involved detailed tracking of the risk of infection in high-risk contacts.�� She worked for 15 years at the National Centre for Immunisation Research, and has conducted many vaccine clinical trials and has expertise in vaccinology and vaccine programs, especially vaccination of adults, at-risk and immunosuppressed populations.

��She is a graduate of the Australian Field Epidemiology Training program, the MAE at ANU, and has extensive experience in shoe-leather epidemiology of infectious diseases outbreaks. Her in-depth understanding of the science of outbreak investigation draws from this experience combined with her academic training through a Masters and PhD in Epidemiology. She is best known for research in the detailed understanding of the transmission dynamics and prevention of infectious diseases, particularly respiratory pathogens such as influenza, tuberculosis,����and vaccine-preventable infections. She has led the largest body of research internationally on����and respirators in health care workers. Her research has been influential in informing��guidelines for health workers on PPE. She has extensive expertise in vaccination programs, with a particular interest in adult vaccination with a focus on the elderly and vaccines for bioterrorism. Specific vaccination interests include influenza, pneumococcal disease, HPV,��,��herpes zoster and SARS-CoV2. She has done a body of work on vaccine effectiveness of��. She led a��NHMRC Centre for Research Excellence in immunisation��for high risk populations,��a vaccine research centre focused on adult and high-risk group vaccination. Her face mask research has focused on health care workers and hospitals. She does cross-disciplinary research on aerosol dynamics and��, in collaboration with aerospace and fluid mechanics engineers at �鶹��madou, and on development of��. She currently leads a MRFF-funded study of airborne transmission of SARS-CoV-2 in hospitals, which seeks to develop real-time monitoring and mitigation of air quality and infection risk. She does similar work in aged care facilities.

She has done research on using risk-analysis methods for analysing the origins of emerging infectious diseases outbreaks and is a leader in new approaches to biosecurity through cross-disciplinary response and��emerging threats to health security.��She is involved in several research studies on COVID-19 and Long COVID. She also designed and co-convened a course,��, taken by students at �鶹��madou and ASU.�� She has led a smallpox����(��2018��and����2019) in Australia and��, which underpinned by modelling research and covers issues such as surveillance, diagnosis, health system capacity, mass quarantine, maritime transport and infected cruise ships, travel bans and the foundations of epidemic control - prescient, as these all came to pass during the COVID-19 pandemic.��

She currently leads a cross-disciplinary��, on mitigation of airborne threats to health, which focuses on aged care, healthcare and community settings.����She led a Centre for Research Excellence in Epidemic Response,��ISER��from 2016-2020.��She has over 450 publications in peer-reviewed journals. Her passion for field epidemiology led her to co-found the��ARM network��for Australian outbreak response.��She is currently on the Global Accreditation Body for TEPHINET, the network of global field epidemiology programs.

She��also has an interest in the ethics of medicine, and specifically in��has been on the World Organisation for Animal Health (OIE) committee for developing Guidelines For Responsible Conduct in Veterinary Research Identifying, Assessing and Managing Dual Use Research. She has research collaborations across the��, with researchers from Arizona State University and Kings College London, and has an adjunct professorships at The College of Public Affairs and Community Solutions and the College of Health Solutions��at ASU. She is an adjunct professor at ASU and was among the��during the COVID pandemic.��She started a new cross-disciplinary journal, published by �鶹��madou,��,��launched in February 2019. She published her first book,��in 2022, which conveys her knowledge and concerns about biosecurity in lay language for non-expert readers. Her new book,��Vaccine Nation - Science, reason and the unravelling of 200 years of progress��will be coming out in 2025 (New South Press). She has talent in art (and wanted to be an artist before deciding on medicine as a career) and creative writing, which flows to her creative talent in medical research and ability to apply creativity to complex research problems.����

See����profile

Interested in Raina's story?��Read��"First Responder"��and��

��

��

��

Research Highlights:

��

o��������She won many career awards including the Sir Henry Wellcome Medal and Prize, from the Association of Military Surgeons of the United States in 2007 for her work on a risk-priority scoring system for category A bioterrorism agents; the Eureka Prize for Leadership and Innovation in Science in 2022 and the highest national award in infectious diseases, the Frank Fenner Award for Research in Infectious Diseases in 2003. She was a finalist in the 2021, 2020 and 2017 Eureka Prizes. In 2021 she received The Women’s Agenda Leadership Award - Frontline Hero and���鶹��madou Medicine ��Value in Action Award for Impact. She won��the CAPHIA Research Team Prize in 2017, The Public Health Association of Australia National Immunisation Achievement Award in 2014, and also the Peter Baume Public Health Impact Prize in 2014. In 2012 she won the �鶹��madou Medicine Dean's award for outstanding achievement, the highest award in the faculty of Medicine. She has previously held a NHMRC PhD scholarship, a NHMRC Career Development Award, NHMRC Principal Research Fellowship and has been a Harkness Fellow. She spent her Harkness fellowship studying the transmission of tuberculosis in prisons in the US, at Johns Hopkins University.

o��������She has published the largest body of clinical trials of face masks in prevention of respiratory infections for health workers internationally, including the only RCT on cloth masks at the time the COVID pandemic began. Her RCTs are cited in policy documents globally, including WHO, CDC, ECDC and others.��

o��������She is an expert in health intelligence, outbreak detection and mitigation, including that arising from bioterrorism and biological warfare, with a deep understanding of epidemic control at the population level. She is a leading global expert on smallpox and orthopoxviruses.

o��������She initiated and led the creation, funding and training of the Network of Infectious Diseases Modellers of Australia through a NHMRC CBG in Population Health. This is a national network spanning three states and five Universities, which has had a prolific research output. She is interested in applying risk analysis methods to public health.

o��������She leads a large program of vaccination clinical research, including studies in frail elderly vaccinology and in immunosuppressed populations such as bone marrow transplant recipients.

Memberships & Professional Activities����

��WHO SAGE Ad Hoc Working Group on Smallpox and Mpox (2022-current)

• WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) 2021-2024 (member)
• United States National Academies of Science, Engineering and Medicine Committee on public health interventions and countermeasures for advancing pandemic and seasonal influenza preparedness and response. Member, 2021.
• Member,��NHMRC National COVID-19 Health and Research Advisory Committee 2020-2021
• Member, NSW Health COVID-19 Vaccine Advisory Group 2020-2021
• Member, Group of 8 advisory group on social distancing for COVID-19, 2020
• Member, Global Accreditation Board, TEPHINET 2017-current
• Member,��World Organisation for Animal Health (OIE) Ad Hoc Committee on Guidelines for Managing Dual Use Research 2018.
• Fellow, Royal Society of NSW (elected 2016)
• Member, Australian��Infection Prevention & Control Ebola Expert Advisory Group - 2014
• Member, WHO SAGE Committee on Varicella and Zoster Vaccine (2013-2014).
• Member, US National Academy of Sciences, Institute of Medicine, Committee on Respiratory Protection for Healthcare Workers Against Novel H1N1 Influenza A, 2009.
• Member of Council, Faculty of Public Health Medicine of Australia (2014-18)
• Member, Word Organization of Medical Editors (WAME) (2003-current)
• Member, Australian Society for Infectious Diseases (1998-2013)
• Member, Public Health Association of Australia - PHAA (current)
• One Health Special Interest Group committee, PHAA (current)
• Fellow, Royal Australasian College of Physicians
• Fellow, Australian Faculty of Public Health Medicine
• Member, Specialist Influenza Advisory Group to the Chief Medical Officer of Australia, 2007-2010
• Member, Pandemic Influenza Advisory Group to the Chief Medical Officer of Australia, 2007-2010
• Member, Association of Military Surgeons of the United States (2007-2009)
• Member, Infectious Diseases Subgroup of the Detention Health Advisory Group, Australia, 2007-.2008
• Member, National Health and Medical Research Council (NHMRC) Expert Advisory Group on Antimicrobial Resistance (EAGAR) (2005-2008).
• Member, Hepatitis B working party of the Ministerial Advisory Committee on AIDS, STDs and Hepatitis.
• Member, Working Parties for the Australian Technical Advisory Group on Immunisation: Influenza, Hepatitis A; Pneumococcal disease; Varicella zoster; Rotavirus������

Editorial Boards

Epidemiology and Infection

BMJ Open

Vaccine Council of 100

Global Biosecurity

��

��

��

��

��

��

��

��

��

��